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Abstract
Among 2012 Docstyle survey respondents, 80% identified doxycycline as the appropriate 
treatment for Rocky Mountain spotted fever in patients ≥8 years old, but only 35% correctly chose 
doxycycline in patients <8 years old. These findings raise concerns about the higher pediatric 
case-fatality rate of Rocky Mountain spotted fever observed nationally. Targeted education efforts 
are needed.
Rocky Mountain spotted fever (RMSF) is a tick-borne disease that poses a significant 
clinical dilemma for physicians, progressing rapidly from a nonspecific febrile illness to 
organ failure and death in some untreated cases.1,2 Fatalities can be avoided with prompt 
empiric treatment with a tetracycline antibiotic, but treatment is most effective when started 
in the first 5 days of illness, and other broad spectrum antibiotics are not effective.3,4 
Doxycycline, as recommended by the American Academy of Pediatrics, is the treatment of 
choice in patients of all ages.5,6 However, in a recent survey in Tennessee, <40% of 
providers correctly identified doxycycline as the treatment of choice in children <8 years 
old.7 We sought to evaluate age-specific national prescribing practices for patients with 
RMSF, using a web-based survey of healthcare providers (HCPs).
Methods
DocStyles is an annual web-based survey conducted by Epocrates, Inc that assesses US HCP 
practices. Respondents were required to currently treat patients and have practiced for ≥3 
years, and were paid an honorarium of $20-$85. The overall response rate for the 2012 
DocStyles survey was 52%. Our analyses were limited to responses from primary care 
physicians, internists, pediatricians, and nurse practitioners (n = 1503). The 2012 survey 
included 2 questions pertaining to the treatment of RMSF: which antibiotic would be their 
first choice of treatment for RMSF in: (1) adults and children 8 years old or older; and (2) 
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children less than 8 years old. “Doxycycline” was the correct answer to both questions, with 
trimethoprim-sulfamethoxazole, chloramphenicol, azithromycin, other, and no antibiotic 
considered incorrect choices. Respondents were also asked how often they used different 
sources of continuing medical education (CME). Pearson χ2 test was used for hypothesis 
testing at α = 0.05.
Results
Generalpractitioners (36%) and internists (31%) were themost frequent respondent type, and 
the majority of respondents (74%) reported seeing pediatric patients in clinical practice 
(Table I).
Most respondents (80%) correctly identified doxycycline as the treatment of choice for 
adults and children 8 years and older (Table II). A minority of respondents (35%) correctly 
identified doxycycline as the treatment of choice for children less than 8 years old, although 
pediatricians responded correctly (51%) more often than other HCPs (32%) (P < .0001). Of 
the respondents who correctly selected doxycycline as the treatment of choice for adults and 
children 8 years and older, 58% failed to identify doxycycline as the treatment of choice in 
children less than 8 years old. Provider characteristics significantly associated with correct 
selection of doxycycline to treat RMSF in children less than 8 years old included male HCP, 
having an exclusive inpatient practice, seeing pediatric patients, having privileges at a 
teaching hospital, and practicing ≤15 years, although none of these characteristics resulted in 
a frequency of doxycycline usage greater than 43%.
Most respondents (76%) reported often or always using journals or the internet for sources 
of CME.
Discussion
A majority of US HCPs failed to identify doxycycline as treatment of choice for RMSF in 
children less than 8 years old, despite its use being recommended by the American Academy 
of Pediatrics.6 In contrast, 80% of HCPs correctly identified doxycycline as the treatment for 
adults and older children. This indicates a significant variation in clinical practice decisions 
based on patient age. Delayed treatment, or treatment with an antibiotic other than a 
tetracycline, carries a risk of fatality from RMSF.4 During 1999–2007, US children aged 0–
9 years were 6 times more likely to die from RMSF compared with older children and 
adults, and children ≤9 years old represented 33% (13/40) of all reported fatalities.1 This 
raises a serious concern that provider decisions may be directly contributing to a preventable 
cause of pediatric mortality.
Provider hesitancy to prescribe doxycycline for children may be based on concerns about 
possible dental staining.8–10 The current doxycycline label indicates that unless there are no 
other effective antibiotics, the drug should be avoided in children less than 8 years old to 
avoid staining of permanent teeth.10 The label does not directly address the fact that there 
are no equally effective alternatives for the treatment of RMSF, or that short courses of 
doxycycline have not been shown to have this effect.8–10 Although inferences regarding 
HCP perceptions of dental staining are limited because this survey did not explore factors 
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influencing treatment decisions, this study points toward an important gap in HCP 
knowledge regarding RMSF treatment that should be addressed with targeted CME using 
journals and internet sites.
Prompt and empiric administration of doxycycline to suspected cases of RMSF in children 
less than 8 years old is one important key to reducing the elevated case-fatality rate in this 
age group. Knowledge of and confidence in doxycycline likely plays a crucial role in 
influencing HCP age-specific prescribing decisions. Additional studies examining the 
effects of doxycycline on developing teeth, as well as possible label changes to reassure 
providers of safety at the recommended dose and duration, may improve compliance with 
national treatment recommendations in children less than 8 years old.
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Table I





 Internist 464 (31%)
 Family/general practitioner 537 (36%)
 Pediatrician 250 (17%)
 Nurse practitioner 252 (17%)
Age group
 25–35 170 (8.7%)
 36–50 778 (52%)
 51–65 522 (37%)
 >65 33 (2.4%)
Sex
 Female 618 (41%)
 Male 885 (59%)
Years in practice
 3–7 270 (17%)
 8–12 411 (26%)
 13–20 396 (27%)
 21–30 367 (26%)
 >30 59 (4.9%)
Patients seen per week
 <50 96 (6.4%)
 50–100 909 (60%)
 101–200 453 (30%)
 201–300 19 (1.3%)
 >300 26 (1.7%)
Pediatric patients
 Yes 1112 (74%)
 No 391 (26%)
Teaching hospital privileges
 Yes 692 (47%)
 No 811 (53%)
Practice type
 Outpatient 1358 (90%)
 Inpatient 145 (9.7%)
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Table II
HCP characteristics associated with correct response to RMSF treatment, bivariate analysis
Doxycycline in patients ≥8 years Doxycycline in patients <8 years
N = 1202 (80%) P value N = 522 (35%) P value
Provider type
 Family/general practitioner 419 (78%) <.0001 161 (30%) <.0001
 Internist 377 (81%) <.0001 157 (34%) <.0001
 Nurse practitioner 174 (69%) <.0001 77 (31%) <.0001
 Pediatrician 232 (93%) Referent 127 (51%) Referent
Provider sex
 Male 717 (81%) .22 326 (37%) .04
 Female 485 (78%) Referent 196 (32%) Referent
Practice type
 Outpatient 1082 (80%) .38 460 (34%) .03
 Inpatient 120 (83%) Referent 62 (43%) Referent
Sees pediatric patients
 Yes 905 (81%) .02 403 (36%) .04
 No 297 (76%) Referent 119 (30%) Referent
Privileges at a teaching hospital
 Yes 564 (82%) .17 258 (37%) .05
 No 638 (79%) Referent 264 (33%) Referent
Years in practice
 ≤15 707 (82%) .04 321 (37%) .02
 >15 495 (77%) Referent 201 (31%) Referent
Patients seen per week
 ≤100 797 (79%) .36 348 (35%) .9
 >100 405 (81%) Referent 174 (35%) Referent
Reported patient financial status
 Very poor to middle class 709 (81%) .10 306 (35%) .7
 Middle class to affluent 493 (78%) Referent 216 (34%) Referent
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